Phil Reason, CEO, gives a comprehensive overview of the investment case for Instem.
Introduction by Gareth Evans, Progressive Equity Research – 00:18
Phil Reason, CEO Introduction – 01:05 What is Instem? – 03:02 Market leader – 06:22 Market drivers – 08:38 INS from discovery to post marketing – 13:13 Study management – 16:42 Regulatory solutions – 19:43 SEND Outsourced Services Growth – 23:04 Informatics – 26:10 Financial highlights H1 19 – 29:50 Summary – 30:20 Q&A – 31:27
Instem plc is a supplier of information technology (IT) applications to the early development healthcare market delivering solutions for data collection, management and analysis across the research and development continuum. The Company is engaged in Global Life Sciences operations. Its lead product suite, Provantis, is an application in the Early Development Safety Assessment (EDSA) market. The Provantis solution incorporates a suite of modules required for managing and recording EDSA studies, from receipt of the compound through to the automated assembly of statistical analyses and final reports. Its software allows scientific staff to collect, analyze and share data across the organization and externally. It also offers ALPHADAS, an early phase clinical software solution. The Company offers Centrus suite, which provides pre-built applications, as well as the ability to utilize a range of business intelligence and analysis tools.